IL-17F Inhibitors & Biosimilars
1 drugsAbout IL-17F
Interleukin-17F (IL-17F) is a cytokine and member of the IL-17 family, playing a crucial role in inflammatory responses and contributing to the pathogenesis of various immune-mediated diseases.
IL-17F is a therapeutic target for immunological disorders, though currently there is no genetic evidence directly linking IL-17F to specific diseases.
IL-17F is targeted by one FDA-approved biologic drug, BIMZELX (UCB INC), indicated for immunology; it was first approved in 2023.
Top IL-17F Drugs
The competitive landscape is dominated by UCB INC, the sole company with an approved drug.
High market concentration indicates potential entry barriers and the need for differentiated therapeutic strategies.
IL-17F Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL-17F, using biologic (other) modality.
The lack of modality diversity suggests an opportunity for small molecule or antibody-based therapeutics targeting IL-17F.
IL-17F Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IL-17F. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 4 | 1 | 2 | 80% |
| Phase 2 | 16 | 12 | 0 | 4 | 100% |
| Phase 3 | 25 | 19 | 0 | 6 | 100% |
| Phase 4 | 5 | 2 | 1 | 2 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
IL-17F Drug Approval Timeline (2023 - 2023)
The first drug targeting IL-17F, BIMZELX, was approved in 2023.
Recent approval suggests an emerging target, but further approvals are needed to confirm long-term viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IL-17F. A trial counts if an approved drug acting on IL-17F is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.